Premier Investments (PMV)
|
|
- Christine Davidson
- 5 years ago
- Views:
Transcription
1 16 March 2018 Analyst Sam Haddad Authorisation Tim Piper Premier Investments (PMV) Key growth pillars all strong Recommendation Buy (unchanged) Price $15.27 Target (12 months) $17.20 (previously $16.90) GICS Sector Retailing Expected Return Capital growth 12.6% Dividend yield 3.9% Total expected return 16.5% Company Data & Ratios Enterprise value Market cap $2,387m $2,426m Issued capital 158.8m Free float 61% Avg. daily val. (52wk) $4.7m 12 month price range $ $15.47 Price Performance (1m) (3m) (12m) Price (A$) Absolute (%) Rel market (%) Absolute Price $18.0 $17.0 $16.0 $15.0 $14.0 $13.0 $12.0 $11.0 Mar 16 Sep 16 Mar 17 Sep 17 Mar 18 PMV S&P 300 Rebased SOURCE: IRESS BELL POTTER SECURITIES LIMITED ACN AFSL Online achieving significant growth, CODB/sales leverage PMV announced underlying 1H18 NPAT of $78.8m, 6.5% up on pcp. The Just Group EBIT of $102.5m was in line with our $103.4 estimate. The result key highlights are: Smiggle continues to grow strongly, shortly to enter Continental Europe: Smiggle continued to achieve strong global LFL sales growth. Including 35 new stores, Smiggle global sales lifted 26.7% to $170.7m (inline vs BPe). In the UK 23 stores were opened with another 7 to 17 openings targeted in 2H18. There were 4 store openings in Australia, 2 & 3 store openings in Malaysia/Hong Kong, and 3 in Ireland. Smiggle is expected to enter the Netherlands in 2QFY19. Peter Alexander tracking ahead of 2020 growth plan: Peter Alexander sales increased 15.0% to $114.4m (inline vs BPe) underpinned by strong LFL growth and 11 store openings. New plus-size range achieved significant growth in 1H18 with Bath & Body and extended Childrenswear range expected to launch in April Peter Alexander is well on track to exceed its $250m sales target by FY20. Online sales achieving significant growth, $100m in sales to be reached in 2018: Online sales, which is significantly higher EBIT margin vs group average, increased 71.2% on pcp to $56.0m. Online is now expected to deliver the original CY20 sales target of $100m in CY18, 2 years ahead of schedule. The significant traction in online clearly demonstrates PMV s leading omni-channel capabilities. Strong operating leverage coming through: CODB/sales decreased 144bps, more than offsetting softer gross margins (due to the competitive environment). The opex leverage reflects a more profitable store mix (note Smiggle salary/sales significant lower vs ANZ group average), online growth and centralised functions. Earnings changes & Investment View: Retain Buy, PT $17.20 There is no material changes to our FY18-FY20 EPS estimates. However time creep & minor model adjustments increases our PT from $16.90 to $ The key takeaway from the result is the continued strong growth across all three key growth pillars, with growth in the online channel particularly strong. At an implied FY18/FY19 EV/EBITDA of ~11.2x/~9.7x for the Just Group, we retain our Buy rating on the stock. Earnings Forecast Jul Year end 2017a 2018e 2019e 2020e Just Group Sales (A$m) 1, , , ,429.8 Total Group Revenue (A$m) 1, , , ,437.3 EBITDA (A$m) NPAT (reported) (A$m) NPAT (underlying) (A$m) EPS underlying (cps) EPS underlying growth (%) 4.1% 8.1% 16.3% 16.1% PER (on underlying EPS) (x) EV/EBITDA (x) Dividend ( ps) Yield (%) 3.5% 3.7% 4.1% 4.6% Franking (%) 100% 100% 100% 100% ROE (%) 8.0% 8.7% 9.9% 11.0% SOURCE: BELL POTTER SECURITIES ESTIMATES DISCLAIMER: THIS REPORT MUST BE READ WITH THE DISCLAIMER ON PAGE 7 THAT FORMS PART OF IT. Page 1
2 The Just Group 1H18 EBIT in line vs BPe Figure 1 - Actual vs expected summary Headline result PMV announced an underlying 1H18 NPAT of $78.8m (bs BPe $81.4m), up 6.5% on pcp. An interim fully franked dividend of 29cps was declared (pcp: 26cps). The Just Group achieved 1H18 underlying EBIT of $102.5m in line with our $103.4m estimate (not shown in Figure 1), and up 10.2% vs pcp. The increase on pcp was driven by both retail sales growth of 7.0% (again not shown in Figure 1), which included constant currency LFL sales growth of 2.4% (cycling 2.1%), as well as retail EBIT margin expansion of 47bps (driven by lower CODB, partially offset by lower gross margin) to 16.3%. Smiggle continued to achieve strong global LFL sales growth. In the UK, the Smiggle store network expanded by 23 stores to 125 at end-1h18, with a further 7 to 17 stores openings flagged in 2H18. In Malaysia/Hong Kong/Ireland, 2/3/3 stores opened respectively, taking the store count to 13/13/5. PMV plans to enter the Netherlands in 2QFY19, with Belgium to follow during CY2019. Actuals History Actual Expected Actual vs 1H16 2H16 1H17 2H17 1H18 1H18e Expected Just Group Sales , % % - Growth (pcp) 4.2% 4.1% 4.1% 7.0% Total Revenue , % % - Growth (pcp) 4.4% 4.0% 4.2% 7.2% EBITDA % %-Margin 17.8% 10.2% 14.3% 17.5% 10.3% 14.2% 17.9% 17.5% 0.4% % - Growth (pcp) 2.6% 5.3% 3.5% 9.5% Depn & Amort % EBIT % %-Margin 15.6% 7.8% 12.0% 15.3% 7.7% 11.8% 15.7% 15.4% 0.4% % - Growth (pcp) 2.3% 3.0% 2.5% 10.1% Net Interest Profit before Tax % Tax Associates/Minorities % Underlying NPAT % %-Margin 12.6% 6.7% 9.9% 12.5% 6.9% 9.9% 12.5% 12.4% 0.1% % - Growth (pcp) 3.4% 7.2% 4.6% 6.5% Abnormals post tax Reported NPAT % DPS ( ps) The core brands achieved mostly positive 1H18 results, as follows: Larger brands: Jay Jays slight positive LFL sales growth; Just Jeans LFL cycled strong comps (pcp: +4.7) and was down -3.6%, although has returned to growth in the first 6 weeks of 2H18. Smaller brands: Portmans and Jacqui-E achieved a strong turnaround in LFL sales performance. Dotti weak, down -7.8% and continues to experience tough competition. As previously noted, management is taking a hard line on rental terms (as leases mature) and is prepared to close stores if incentives from landlords do not improve. This is especially the case in the youth fast fashion category (i.e. for Dotti) where landlords have Page 2
3 Net Debt (-ve) / Net Cash (+ve) provided more favourable terms to new international entrants. During the half PMV closed 10 stores across the group (net store openings totalled 43 stores across the group). Balance sheet and cashflow PMV has a strong balance sheet with net cash at hand (Figure 2). As at end-1h18 net cash stood at $38.9m which includes $185.5m in free cash held by PMV, $77.6m debt at the Just Group level that is non-recourse to PMV, plus $69m in borrowings secured by two mortgages over the recently acquired DC ($19m) and head office building ($50m). The reduction in net cash vs pcp reflects PMV s $100.4m investment in Myer (~10.8% stake). Return metrics at first glance appear low (Figure 3), although this in part is attributed by the significant lift in retained earnings arising from the ~$791m pre-tax gain on the Coles Group Limited disposal in FY07. Dilution is also attributed to the part equity-funded acquisition of Just Group in. Looking forward we expect return metrics will continue to improve alongside growth in Just Group earnings. A step-up is also likely if a material acquisition is made with either no or limited new equity capital funding support. Figure 2 Net cash/net debt group balance sheet position Figure 3 - Return metrics % 10% 8% 6% 4% 2% 0% ROIC ROE Cash flow metrics are sound as illustrated by PMV s healthy 80%-100% gross cash flow conversion in Figure 4. Figure 5 charts PMV s free cash realisation. Figure 4 EBITDA to cashflow conversion Figure 5 - Free cash realisation 120% % 100% % 80% 60% % 50% 40% 40 0% 20% 0% 0-50% Free cashflow ($m) - LHS Free Cash Realisation (%) - RHS Earnings revision summary There is no material (<3%) changes to our FY18/FY19/FY20 EPS estimates. However time creep and minor model adjustments increases our 12-month price target from $16.90 to $ Figure 6 provides a summary of our forecast changes for FY18-FY20. Page 3
4 Figure 6 Earnings revisions summary Old New % Change Old New % Change Old New % Change Revenue $m % % % EBITDA $m % % % EBITDA Margin % 14.5% 14.5% 0.0% 15.3% 15.1% -0.2% 16.2% 16.0% -0.2% Underlying NPAT $m % % % Underlying EPS ps % % % DPS ps % % % Implied valuation for The Just Group In Figure 7 we derive the implied EBITDA multiple beginning with PMV s current market capitalisation. We treat PMV s associate holding in BRG as an investment available for sale for this exercise. Our value for PMV s BRG and MYR investments are based on their market trading value minus an estimate of deferred tax liability, post a 5% discount to account for equity market risk. Figure 7 The Just Group implied valuation multiple analysis $'m $/share Premier Investments - Market Cap 2, Less net cash/add net debt Breville Group - Investment Myer Group - Investment Implied Value of Just Group (Calc. = "PMV Mkt Cap - Net Cash - BRG/MYR Investment") 1, Franking Credit Balance (end-) - (Not included in calc) Implied Multiple for Just Group Just Group EBITDA EBITDA Mulliple BRG/MYR value is calculated based on its market trading value minus deferred tax liability (estimate) and post a 5% discount We believe The Just Group s implied FY18/FY19 EV/EBITDA multiple of 11.2x/9.7x is undemanding considering the business strong management team, solid growth in key core brands (notwithstanding macro challenges) and significant long-term growth prospects in Smiggle/Peter Alexander/online. Furthermore, there is upside potential from acquisitions (either integrated as part of, or separate to The Just Group). Page 4
5 Premier Investments Company Description Premier Investments (PMV) is an investment company whose major investment is in clothing retailer Just Group. Just Group operates specialty retail brands Just Jeans, Jay Jays, Portman s, Jacqui E, Peter Alexander, Dotti and Smiggle. Just Group currently operates over 1,200 stores globally including approximately 60 stores in South Africa via a joint Venture. PMV also has major stakes in Breville group (BRG) and Myer Holdings (MYR) as well as c$170m in cash excluding non-recourse debt held within the Just group. Investment Strategy PMV aims to maximise long term growth in capital returns to shareholders through being an owner/manager of Australian focused companies with a particular concentration on the areas of retailing, importing and distributing. We believe PMV s strategy will succeed in the face of increasing competition from global brands in fast-fashion retailing. A key potential catalyst remains the utilisation of their cash and franking credits in the form of an acquisition or capital management. We have a BUY recommendation. Valuation Our blended 12-month PT is $ Our SOTP (EV/EBITDA basis) is $16.20, while our DCF is $18.19 (WACC of 10.7%). We take a simple average to derive our price target. Risks Key downside risks to our valuation include (but are not limited to): Slowdown in consumer spending and rise in unemployment - Just Group s product portfolio is mainly clothing and accessories which are highly discretionary items. Rising competition from international peers Impingement of market share arising from increased competition from global retailers such as Zara, Top Shop and H&M. Brand positioning and product offering It is crucial to keep up with the latest fashion trends and right product mix for the targeted customer group. Failure to do so can result in declining sales and loss of customer loyalty. Unseasonal weather Unseasonal weather results in a miss-match between in-store product offering and weather conditions, reducing demand. Online retailing The increased acceptance of internet based shopping remains a competitive risk issue. We believe PMV has suitably addressed this risk through its omni-channel capabilities. Movements in the foreign exchange rates - PMV directly imports 60% to 70% of their products from overseas. The greatest currency sensitivity is to the AUD/USD. Supply chain risks Fast-retailing is highly dependent on efficiently getting product to market. Delays in supply chain could result in product missing key seasonal periods. Management risk - Loss of Just Group Management. Key person risk in PMV Chairman, Solomon Lew who has substantial retail experience. Store rollout changes This could impact our incremental revenue/earnings forecast. Acquisition risk Potential oversights during the due diligence process, strategic fit with broader PMV portfolio, integration risk and multiple paid. Page 5
6 Premier Investments as at 16 March 2018 Recommendation Buy Price $15.27 Target (12 months) $17.20 Table 1 - Financial summary Jul Year end e 2019e 2020e Price $15.27 Profit & Loss (A$m) Recommendation Buy Just Group Sales , , , , ,429.8 Diluted issued capital (m) Change 6.2% 10.7% 4.1% 8.2% 10.1% 9.8% Market cap ($m) 2,425.5 Other rev/income Target Price (A$ps) $ Total Group Revenues , , , , , Change 5.9% 10.4% 4.2% 8.5% 10.2% 9.8% Jul Year end e 2019e 2020e EBITDA Valuation Ratios... Change 11.0% 22.7% 3.5% 10.8% 14.6% 16.3% Underlying EPS ( ps) Deprec. & amort. (22.7) (23.9) (26.1) (27.1) (30.7) (35.7)... % change 11.8% 17.6% 4.1% 8.1% 16.3% 16.1% EBIT PE (on underlying EPS) (x) Net Interest (0.1) (2.5) (1.7) (1.6) EV/EBITDA (x) Pre-tax profit EV/EBIT (x) Tax expense (28.8) (39.2) (35.5) (41.3) (47.6) (55.9)... tax rate 28% 30% 27% 29% 29% 29% NTA ($ps) Associates P/NTA (x) Minorities/Prefs Book Value ($ps) Underlying Net Profit Price/Book (x) Change 12.5% 17.9% 4.6% 8.2% 16.3% 16.1% Abs. & extras. - - (3.5) (0.2) - - DPS ( ps) Reported Profit % pay-out 90.4% 72.5% 76.9% 76.8% 72.5% 69.8% Special DPS ( ps) Underlying Net Profit Yield (%) 3.3% 3.1% 3.5% 3.7% 4.1% 4.6% Pro-forma Adjs (BRG accounting change) Franking (%) 100% 100% 100% 100% 100% 100% Adj. Net Profit (pro-forma /) Change 12.5% 17.9% 4.6% 8.2% 16.3% 16.1% Performance Ratios Revenue growth (%) 5.9% 10.4% 4.2% 8.5% 10.2% 9.8% Cashflow (A$m) EBITDA growth (%) 11.0% 22.7% 3.5% 10.8% 14.6% 16.3% EBITDA EBITDA/sales margin (%) 12.9% 14.3% 14.2% 14.5% 15.1% 16.0% Working capital changes (4.3) (14.6) (25.9) 13.7 (17.9) (8.7) EBIT/sales margin (%) 10.5% 12.0% 11.8% 12.2% 12.7% 13.5% Net Interest Expense (2.5) (1.7) (1.6) Gross cash conversion (%) 89.1% 84.3% 87.1% 101.7% 86.6% 91.2% Tax (22.3) (37.8) (51.4) (59.1) (45.3) (53.3) Free cash-flow yield (%) 2.8% 2.4% 2.1% 3.5% 3.8% 5.0% Other operating items ROE (%) 6.6% 7.7% 8.0% 8.7% 9.9% 11.0% Operating Cash Flow ROIC (%) 7.3% 8.8% 8.5% 8.8% 9.9% 11.1% Capex (36.1) (45.0) (47.6) (45.0) (48.9) (53.6) Capex/Depn (x) Free Cash Flow Acquisitions (16.5) (0.0) (102.4) Net interest cover (x) n/a n/a 1, Disposals Net Debt/EBITDA (x) n/a n/a 0.0 n/a 0.0 n/a Dividends paid (78.0) (69.0) (80.4) (88.4) (93.7) (105.8) Net debt/equity (%) -13.2% -13.3% 0.2% -0.1% 0.0% -1.0% Other investing items (47.8) Net debt/net debt + equity (%) -15.2% -15.3% 0.2% -0.1% 0.0% -1.1% Equity Debt increase/(reduction) (13.8) (15.5) Component Contribution Just Group sales rev , , , , ,429.8 Balance Sheet (A$m) Other Just Group rev Cash MYR dividend income Receivables Corp./elimin. sales Inventories & WIP Total Revenue (A$m) , , , , ,437.3 Other current assets Current Assets Just Group EBIT Receivables Other/corp/elim. EBIT (5.7) (7.0) (6.6) (5.5) (7.1) (9.0) Assoc & investments Total EBIT (ex. Associates) (A$m) Fixed Assets Intangibles Half yearly (A$m) 1H16 2H16 1H17 2H17 1H18 2H18e Other mom-curr assets Sales revenue Non Current Assets 1, , , , , ,483.8 EBITDA Total Assets 1, , , , , ,899.2 Deprec. & amort. (12.3) (11.6) (13.0) (13.1) (13.7) (13.4) ST and LT debt EBIT Creditors Interest expense (1.0) (1.9) (0.6) Provisions Pre-tax profit Other liabilities Tax expense (26.8) (12.4) (26.6) (8.9) (28.8) (12.6) Total Liabilities tax rate 30% 31% 29% 23% 29% 28% Net Assets 1, , , , , ,451.6 Associates Share Capital Minorities Reserves 32.2 (2.4) (30.1) (27.8) (27.8) (27.8) Underlying Net Profit Retained Earnings Abs. & extras. - - (2.1) (1.4) (0.2) - Shareholders Equity 1, , , , , ,451.6 Reported Profit Outside Equity Interests Total Equity 1, , , , , ,451.6 Net debt/(cash) $m (176.9) (177.4) 2.8 (1.5) 0.2 (15.2) SOURCE: BELL POTTER SECURITIES ESTIMATES Page 6
7 Recommendation structure Buy: Expect >15% total return on a 12 month view. For stocks regarded as Speculative a return of >30% is expected. Research Team Staff Member TS Lim Sam Haddad Chris Savage Title/Sector Head of Research Phone tslim shaddad csavage Hold: Expect total return between -5% Jonathan Snape jsnape and 15% on a 12 month view Tim Piper tpiper Sell: Expect <-5% total return on a 12 month view John Hester Tanushree Jain Financials Healthcare Healthcare/Biotech jhester tnjain Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet. Such investments may carry an TS Lim Lafitani Sotiriou Peter Arden David Coates Duncan Hughes Analysts James Filius Alexander McLean Banks/Regionals Diversified Financials Analyst Analyst tslim lsotiriou parden dcoates dhughes jfilius amclean exceptionally high level of capital risk and volatility of returns. Bell Potter Securities Limited ACN Level 38, Aurora Place 88 Phillip Street, Sydney 2000 Telephone The following may affect your legal rights. Important Disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client s financial situation, particular needs and investment objectives ( relevant personal circumstances ), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. ANALYST CERTIFICATION Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Page 7
Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions
16 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation TS Lim 612 8224 2810 Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously
More informationPlatinum Asset Management (PTM)
24 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90
More informationBWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES
9 February 2017 Analyst John O'Shea 613 9235 1633 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $4.80 Target (12 months) $5.73 (unchanged) Expected Return Capital growth
More informationOneVue Holdings (OVH)
7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation
More informationAdacel Technologies (ADA)
9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously
More informationOneVue Holdings (OVH)
24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)
More informationPremier Investments (PMV)
4 April 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 Premier Investments (PMV) The Myers touch Recommendation Buy (unchanged) Price $14.20 Target (12 months) $17.65 (previously
More informationNanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES
21 February 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) Growth Slowly Emerging In Europe Recommendation Hold (unchanged) Price $2.80 Target (12 months) $3.20
More informationSurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns
26 November 20 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 SurfStitch (SRF) Shaping the Surf industry Recommendation Buy (unchanged) Price $2.06 Target (12 months) $2.65 (previously
More informationMayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.
29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89
More informationIPH Limited (IPH) Buy at the bottom
29 March 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 IPH Limited (IPH) Buy at the bottom Recommendation Buy (unchanged) Price $4.76 Target (12 months) $7.90 (unchanged) Expected
More informationChallenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES
14 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Challenger (CGF) Expanding the potential Recommendation Buy (unchanged)
More informationCyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Cyclopharm (CYC) 5 March 2018 Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationNanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES
16 January 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) US Market Continues To Expand Recommendation Hold (unchanged) Price $3.16 Target (12 months) $3.28
More informationFortescue Metals Group Ltd (FMG)
3 March 2017 Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Fortescue Metals Group Ltd (FMG) All about the iron ore price Recommendation Sell (unchanged) Price $6.62 Target
More informationOsprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55
27 February 2017 Analyst John Hester 612 8224 2871 Authorisation Tanushree Jain 612 8224 2849 Recommendation Buy (unchanged) Price $0.415 Valuation $0.55 (unchanged) Risk Speculative GICS Sector Healthcare
More informationANZ Banking Group (ANZ)
1 May 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $27.47 Target (12 months) $30.20 (unchanged) GICS Sector Banks Expected Return Capital
More informationAuswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps
24 August 2018 TS Lim 612 8224 2810 Authorisation Tim Piper 612 8224 2825 Recommendation Buy (unchanged) Price $5.71 Target (12 months) $6.20 (previously $5.80) GICS Sector Banks Expected Return Capital
More informationANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES
17 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 ANZ Bank (ANZ) Unquestionably strong 1Q17 Recommendation Buy (Hold) Price $30.21 Target (12 months) $33.25 (previously
More informationAeon Metals Limited (AML)
Analyst David Coates 612 8224 2887 Authorisation Stuart Howe 613 9235 1856 Speculative See key risks on Page 4 Speculative securities may not be suitable for retail clients 22 March 2019 Aeon Metals Limited
More informationNational Australia Bank (NAB)
6 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $30.39 Target (12 months) $32.50 (previously $30.00) Expected Return Capital growth
More informationWestgold Resources (WGX)
3 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.36 Target (12 months) $2.15 (unchanged) Expected Return Capital growth
More informationOsprey Medical (OSP)
18 October 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Osprey Medical (OSP) Harvey and Irma Curtail Growth Speculative See key risks on Page 5 and Biotechnology Risk Warning
More informationMetals X Limited (MLX)
16 July 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.655 Target (12 months) $0.95 (previously $0.98) Expected Return Capital growth
More informationCommonwealth Bank (CBA)
10 February 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Commonwealth Bank (CBA) Ordeal and triumph Recommendation Buy (unchanged) Price $74.20 Target (12 months) $83.50 (previously
More informationMetals X Limited (MLX)
5 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.515 Target (12 months) $0.90 (previously $0.95) Expected Return Capital
More informationMetals X Limited (MLX)
19 April 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.76 Target (12 months) $0.98 (previously $1.00) Expected Return Capital growth
More informationGalaxy Resources Ltd (GXY)
27 March 2018 Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Galaxy Resources Ltd (GXY) Mt Cattlin doing what it is meant to Recommendation Buy Price $3.16 Price Target $4.75
More informationGalaxy Resources Ltd (GXY)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $1.835 Valuation $3.35 (unchanged) -------------- Risk Speculative Expected Return Capital
More informationNational Australia Bank (NAB)
29 March 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $25.62 Target (12 months) $29.50 (unchanged) Expected Return Capital growth 15.1%
More informationBreaker Resources NL (BRB)
David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Speculative See key risks on Page 6. Speculative securities may not be suitable for retail clients 8 February 2019 Breaker NL (BRB) More
More informationTech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e
22 March 2017 Analyst Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Tech Sector Key picks unchanged: IRI, APX, ADA & IFM Stock Price Target Rating ADA $2.37 $3.25 Buy ALU $7.41 $7.90 Hold
More informationPeet Bonds (PPCHA) A yield uplift from fixed rate senior debt
4 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 (PPCHA) Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code Peet PPCHA Face value $100 Estimated
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More informationBreaker Resources NL (BRB)
Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Recommendation Buy (unchanged) Price $0.315 Valuation $0.96 (previously $1.30) Risk Speculative GICS Sector Materials Expected
More informationFortescue Metals Group (FMG)
30 October 2015 Analyst David Coates 612 8224 2887 Authorisation John Hester 612 8224 2871 Recommendation Buy (Hold) Price $2.09 Target (12 months) $2.40 (unchanged) Expected Return Capital growth 14.8%
More informationMesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt
7 March 2017 Analyst Tanushree Jain 612 8224 2849 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $1.90 Valuation $3.22 (previously $3.17) Risk Speculative GICS Sector Pharmaceuticals
More information7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date
6 July 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 William Spraggett 613 9235 1733 Whitefield Resettable Preference Shares (WHFPB) Authorisation John Gleeson 612 9255 7220
More informationPioneer Credit (PNC)
23 June 2014 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 Pioneer Credit (PNC) Helping not chasing Recommendation Buy (Initiation) Price $1.55 Target (12 months) $1.80 Expected
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationA mixed bag. Earnings and target price revision. Price catalyst. Catalyst: FY14 results. Action and recommendation
AUSTRALIA PMV AU Price (at 06:10, 17 Sep 2013 GMT) Neutral A$8.38 Valuation - Sum of Parts A$ 7.47-8.01 12-month target A$ 8.50 12-month TSR % +6.1 Volatility Index Low/Medium GICS sector Retailing Market
More informationSt George Mining Ltd (SGQ)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $0.225 Valuation $0.30 (previously $0.26) Risk Speculative Expected Return Capital growth
More informationNoni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts
Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of
More informationAsset revaluation driven by almonds
Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of
More informationPremier Investments. Smiggle proving a four leaf clover A$13.79 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA PMV AU Price (at 05:28, 21 Mar 2017 GMT) Outperform A$13.79 Valuation - Sum of Parts A$ 16.46 12-month target A$ 17.19 12-month TSR % +28.7 Volatility Index Low/Medium GICS sector Retailing Market
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.41 Valuation $0.88 (previously $1.00) Risk Speculative Expected Return Capital growth
More informationParagon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality
26 September 2014 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Paragon Care (PGC) Big Boxes, Big Opportunity Recommendation Buy (Initiation) Price $0.33 Target (12 months) $0.38
More informationUBS Investment Research Brambles Limited
UBS Investment Research Brambles Limited FY12 result: strong revenue momentum Result highlights strong revenue momentum Brambles FY12 result was slightly ahead of expectations, revealing 11% underlying
More informationWestgold Resources (WGX)
7 February 2017 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $2.25 Target (12 months) $2.60 Expected Return Capital growth 15.6% Dividend
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More informationMEDICAL DEVELOPMENTS INTERNATIONAL LTD
MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08
More informationPremier Investments. Making a move? A$14.18 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA PMV AU Price (at 09:06, 29 Mar 2017 GMT) Outperform A$14.18 Valuation - Sum of Parts A$ 17.19 12-month target A$ 17.92 12-month TSR % +30.4 Volatility Index Low/Medium GICS sector Retailing Market
More informationMetals X Limited (MLX)
1 November 2016 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.38 Target (12 months) $2.10 (unchanged) Expected Return Capital growth
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationNoni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) BUY: Acquisition may signal the end of discounting in mature womenswear Noni B Group has agreed to acquire 5 brands from Specialty Fashion Group. Funded by
More informationStrike Energy Ltd (STX)
Analyst Peter Arden 613 9235 1833 Authorisation Stuart Howe 613 9235 1782 Recommendation Buy (unchanged) Price $0.115 Valuation $0.26 (previously $0.23) Risk Speculative Expected Return Capital growth
More informationMotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts
Date Theme Company Update Company MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction We moderate to HOLD (from Buy) with a revised target of $2.36 p/share. We were previously encouraged
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationValue at the top end. Figure 1: Trading margins on debt and equity securities
17 February 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Steve Goldberg 612 8224 2809 Westpac Convertible Preference Shares (WBCPC) Fixed Interest Issue overview
More informationAspire Mining Ltd (AKM)
4 June 2012 Analyst Stuart Howe 613 9235 1782 Fred Truong 613 9235 1629 Authorisation Jonathan Snape 613 9235 1601 Aspire Mining Ltd (AKM) Ovoot PFS released Recommendation Buy (unchanged) Price $0.13
More informationCOMPUMEDICS LTD HOLD. CMP Downgrades FY17 Guidance COMPANY UPDATE EVENT KEY TAKE-AWAYS INVESTMENT VIEW
COMPUMEDICS LTD HOLD CMP Downgrades FY17 Guidance Health Care Equipment & Services / Health Care Equipment 7 July 2017 COMPANY UPDATE Ticker CMP Stock Price $0.560 Target Price $0.530 Forecast Capital
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Interim result draws a line in the sand Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace-lending sector. The company has
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationFamily Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation
BW EQUITIES RESEARCH 14 March 2017 Family Zone Cyber Safety Limited (FZO) Company Update BUY Rating: Target Price 1 : $0.46 Projected Return: 109% 1 12 month target Company Statistics Share Price (A$)
More informationWINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW
WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital
More informationBoart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index
More informationMesoblast (MSB) Major CHF catalyst next week, Time to get on board
9 November 2018 Analyst Tanushree Jain 612 8224 2849 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $2.18 Valuation $4.06 (previously $3.95) Risk Speculative GICS Sector Pharmaceuticals
More informationAppen Limited (APX-AU) 29 August 2017
Appen Limited (APX-AU) 29 August 2017 Pricing in another Upgrade Marketperform Adam Dellaverde adamd@taylorcollison.com.au +618 8217 3923 +6403 013 032 Summary Market capitalisation ($m) $438.7 Share price
More informationInsurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates
11 May 2018 RECOMMENDATIONS AUB Group (AUB) Rating HOLD Risk Low Price Target $14.50 Share Price $14.17 Steadfast Group (SDF) Rating HOLD Risk Low Price Target $2.80 Share Price $2.88 RESEARCH ANALYST
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The
More informationZespri. Vote for change and SunGold licence sales underpin a strong outlook COMPANY RESEARCH. Private Wealth Research
COMPANY RESEARCH 8 MAY 218 Private Wealth Research Zespri Vote for change and SunGold licence sales underpin a strong outlook Key data Code Current price ZGL NZ$8.7 Over the past 6 months since our initiation
More informationSomnoMed (SOM) BUY: US channel conflicts abating in Q4. Key points. Risks and catalysts
Date 27 April 2017 Theme Company Update Company SomnoMed (SOM) BUY: US channel conflicts abating in Q4 We maintain a BUY rating and 12-month price target of $4.50 per share. SomnoMed s Q3 update was a
More informationCash Converters Intl.
MICROCAP COMPANY RESEARCH Cash Converters Intl. 22 nd November 2012 GICS: Diversified Financials Consumer Finance 1Q13 Trading Update RECENT NEW S Cash Converters [ASX:CCV] recently provided a trading
More informationFor personal use only
21 March 2013 Premier Investments consolidatedd NPAT up 20.7% Premier Retail (The Just Group) 1H13 profit before tax up 14.7% Increased interim dividend of 19 cents per share HIGHLIGHTS Premier Investments
More informationCogState Limited (CGS)
CogState Limited (CGS) 26 August 2010 Outperform FY10 NPAT of $1.6m; Launches Axon Sports JV $0.24 Thomas Duthy PhD MBA tduthy@taylorcollison.com.au +61 2 9377 1500 Summary Market Capitalisation (M) $15.8
More informationPRICE $1.30 Regional Express Holdings Ltd REX
16 November 2006 PRICE $1.30 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115M Market cap A$133M
More informationCompany Review 1300SMILES. Corporate Activity Dental Partners. ONT A$6.72 (TP $6.26) Recommendation Hold (no change) Risk Assessment Medium
Ord Minnett Research 2 October 2013 1300SMILES Corporate Activity Dental Partners Event: A consortium led by private equity firm, Archer Capital has recently made an indicative offer for 100% of New Zealand
More informationCREDIBLE LABS INC BUY. Partnership Marketing Strategy Paying Off EVENT COMPANY UPDATE HIGHLIGHTS INVESTMENT VIEW. Q4 Activities Report.
CREDIBLE LABS INC BUY Partnership Marketing Strategy Paying Off Diversified Financials / Other Diversified Financial Services 31 January 2019 COMPANY UPDATE Ticker CRD Stock Price $0.750 Target Price $1.470
More informationRide the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
17 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code BELL POTTER SECURITIES LIMITED ACN
More informationJUST GROUP ENTERS NEXT PHASE OF GROWTH WITH 2 ND HALF EARNINGS PER SHARE UP 20.8% AND FULL YEAR EARNINGS PER SHARE UP 13.7%
ASX RELEASE 12 September 2007 JUST GROUP ENTERS NEXT PHASE OF GROWTH WITH 2 ND HALF EARNINGS PER SHARE UP 20.8 AND FULL YEAR EARNINGS PER SHARE UP 13.7 A pleasing result with a strong second half and well
More informationFila Korea (081660) Widespread growth potential
Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)
More informationMNF Group Limited (MNF)
MNF Group Limited (MNF) 16 February 2018 Outperform 1H18 Results: Excessive Sell-off Presents Buying Opportunity $5.14 Chris Reindler creindler@taylorcollison.com.au +61 2 9210 1335 Summary (AUD) Market
More informationFor personal use only
17 September 2013 Premier increases profit and dividend for FY2013 Premier Investments consolidated reported NPAT of $174.5m Premier Retail NPBT up 9.3% Total full year dividends increased to 38 cents
More informationPRICE $1.16 Regional Express Holdings Ltd REX
13 September 2006 PRICE $1.16 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$121.9M
More informationCooks Global Foods. Focused on capital requirements results restated. CGF budgets for 650 stores, targets 800 by 2021
Cooks Global Foods Focused on capital requirements Company update Food & beverages Cooks Global Foods (CGF) has reaffirmed its 650-store budget for Esquires Coffee by March 2021, but has acknowledged that
More informationZealand Cash on hand n 2
25 March 2014 Premier increases profit and dividend forr 1H14 Premier Consolidatedd 1H14 NPAT of $52.1m and interim dividend of 20cpss fully franked Premier Retail (The Just Group) profit before tax up
More informationStock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016
Stock Focus Pioneer Credit (PNC) Tuesday, 12 April 2016. $2.03 $2.48 $1.69 Share Price $2.82 Positive Neutral Negative Trading Data Last Price $1.70 12 month range $1.53 - $1.85 Market Cap $78m Free Float
More informationPlatinum Asset Management
AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium
More informationMacquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS
23 November 2015 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Macquarie Group Capital Notes 2 (MQGPB) TS Lim 612 8224 2810 Fixed Interest Issue overview Issuer Issue
More information16-Jan Jul Oct Apr Sep Feb Dec Aug Nov May-09
16-Mar-09 16-Apr-09 16-May-09 16-Jun-09 16-Jul-09 16-Aug-09 16-Sep-09 16-Oct-09 16-Nov-09 16-Dec-09 16-Jan-10 16-Feb-10 200 180 160 140 120 100 80 60 40 20 0 PJ 2014 2015 2016 2017 2018 2019 BG 90 60
More informationMEDIA RELEASE JUST GROUP S FIRST HALF NET PROFIT UP 9.0% ANNOUNCES SOUTH AFRICAN JOINT VENTURE AND OFF-MARKET SHARE BUY-BACK
7 March 2007 MEDIA RELEASE JUST GROUP S FIRST HALF NET PROFIT UP 9.0% ANNOUNCES SOUTH AFRICAN JOINT VENTURE AND OFF-MARKET SHARE BUY-BACK Just Group today announced a net profit of $39.7 million for the
More informationNanosonics Limited. Australia Health Care Equipment & Supplies. Growth outlook unchanged. Earnings Forecasts. Source Company, LINWAR Research
LINWAR Securities 30 August 2011 Nanosonics Limited Australia Health Care Equipment & Supplies Outperform (Unchanged) Price: Target Price: Stock's expected return (12mth) $0.57 $1.20 Capital growth 112.4%
More informationGeneration Healthcare REIT
AUSTRALIA GHC AU Price (at 06:13, 24 Aug 2015 GMT) Neutral A$1.65 Valuation - Sum of Parts A$ 1.51-1.59 12-month target A$ 1.59 12-month TSR % +1.8 Volatility Index Low GICS sector Real Estate Market cap
More informationWisr Ltd. New products to underpin growth
Wisr Ltd Company Update New products to underpin growth Wisr Limited (WZR.AX) is an online consumer lending platform focused on financial wellness and competing in the rapidly growing marketplace lending
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationNanosonics (NAN) 1H17: Cash earnings beat grabs attention. Key points
Date 21 February 2017 Theme Financial Results Company Nanosonics (NAN) 1H17: Cash earnings beat grabs attention We maintain our BUY rating with a revised price target of $3.72 per share. NAN shares have
More informationO'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit
EQUITY RESEARCH QUARTERLY UPDATE July 27, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $300.00 ORLY - NASDAQ $277.51 3-5 Yr. EPS Gr. Rate 18% 52-Wk Range $284.66-$225.12 Shares Outstanding 99.4M
More information22 February 2018 Ian Munro
22 February 2018 Ian Munro imunro@ccz.com.au 03 8605 7902 Recommendation: BUY, target price $0.43 (from $0.50) Share price: $0.36 Market cap: $103.7m Year end June 2016A 2017A 2018E 2019E 2020E Sales ($m)
More informationSilver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SIV AU Price (at 08:50, 21 Mar 2017 GMT) Neutral A$7.71 Valuation - PER A$ 6.68 12-month target A$ 6.68 12-month TSR % -7.4 Volatility Index Medium GICS sector Capital Goods Market cap A$m 278
More information